Image

129Xe MRI Cardiopulmonary

129Xe MRI Cardiopulmonary

Recruiting
18 years and older
All
Phase 2

Powered by AI

Overview

The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.

Description

This study focuses on the markers that are derived from the interaction of 129Xe with pulmonary capillary red blood cells (RBCs). Specifically, the investigators focus on RBC transfer MRI, cardiogenic oscillations in 129Xe-RBC signal amplitude, and the 129Xe-RBC chemical shift.

In addition to healthy volunteers, the population to be studied will consist of patients scheduled to undergo either transfusion or phlebotomy, those with a physician diagnosis of interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonias (NSIP), chronic hypersensitivity pneumonitis (cHP), and sarcoid, as well as those with either chronic thromboembolic pulmonary hypertension (CTEPH) and acute pulmonary embolism.

Eligibility

Inclusion Criteria for Healthy Volunteers:

        (Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be
        eligible for enrollment into the trial)
          1. Outpatients of either gender, age > 18
          2. Willing and able to give informed consent and adhere to visit/protocol (Consent must
             be given before any study procedures are performed.)
          3. Subject has no diagnosed pulmonary conditions
          4. Subject has not smoked in the previous 5 years
          5. Smoking history, if any, is less than or equal to 5 pack-years
          6. No history of using other inhaled products more than 1/week for > 1 year
        Inclusion Criteria for Transfusion and Phlebotomy Patients:
          1. In-patient or outpatients of either sex, age > 18
          2. Willing and able to give informed consent and adhere to visit/protocol
        And one of the following:
          1. Patients who are scheduled to receive a red cell transfusion for anemia.
          2. Patients who are scheduled to undergo therapeutic phlebotomy to treat erythrocytosis
             or polycythemia
          3. Healthy volunteers undergoing voluntary whole blood donation (healthy volunteer
             inclusion criteria noted above)
        Inclusion Criteria for Oxygen Administration Patients:
          1. In-patient or outpatients of either sex, age > 18
          2. Willing and able to give informed consent and adhere to visit/protocol
        And one of the following categories (ILD, CTEPH, or Healthy):
          1. Interstitial Lung Disease
               -  Physician diagnosis of Interstitial Lung Disease by a pulmonologist using
                  established criteria
             OR
          2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
               -  Patients with a diagnosis of CTEPH, defined as mean PA pressure >20 mmHg with a
                  pulmonary vascular resistance >2 WU and pulmonary capillary wedge pressure ≤15
                  mmHg at right heart catheterization with evidence of chronic thromboembolic
                  disease on clinical imaging after 3 months of anticoagulation
               -  Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to
                  re-turn 3-6 months after for optional follow-up scans
             OR
          3. Healthy Volunteer (criteria noted above)
        Inclusion Criteria for Acute or Chronic Pulmonary Embolism Patients:
          1. In-patient or outpatients of either sex, age > 18
          2. Willing and able to give informed consent and adhere to visit/protocol
        And one of the following categories (Acute or Chronic)
          1. Acute Pulmonary Embolism
               -  Patients presenting with acute PE 24-48hrs post-admission
               -  Willing to return after 3-6 months of anti-coagulation therapy
             OR
          2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
               -  Patients with a diagnosis of CTEPH, defined as mean PA pressure >20 mmHg with a
                  pulmonary vascular resistance >2 WU and pulmonary capillary wedge pressure ≤15
                  mmHg at right heart catheterization with evidence of chronic thromboembolic
                  disease on clinical imaging after 3 months of anticoagulation
               -  Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to
                  re-turn 3-6 months after for optional follow-up scans
        Exclusion Criteria for All subjects:
        Subjects presenting with any of the following will not be included in the trial:
          1. MRI is contraindicated based on responses to MRI screening questionnaire
          2. Subject is pregnant or lactating
          3. Resting O2 saturation <90% with maximum supplemental O2 delivered by nasal canula
          4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI
          5. Subject has history of any known ventricular cardiac arrhythmia
          6. Subject has history of cardiac arrest within the last year
          7. Subject does not fit into 129Xe vest coil used for MRI
          8. Subject cannot hold his/her breath for 10 seconds
          9. Subject deemed unlikely to be able to comply with instructions during imaging
         10. Medical or psychological conditions which, in the opinion of the investigator, might
             create undue risk to the subject or interfere with the subject's ability to comply
             with the protocol requirements

Study details
    Interstitial Lung Disease
    Chronic Thromboembolic Pulmonary Hypertension
    Acute Pulmonary Embolism
    Anemia
    Polycythemia

NCT06038630

Bastiaan Driehuys

26 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.